Kala Ready To Head Into Clinic With Topical Kinase Inhibitor For Wet AMD
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech hopes to improve upon injectable ophthalmology drugs with a nanotech-based topical drug that will provide less discomfort, while providing better targeting and lower dosing.